incretin mimetic agents glp 1 receptor agonists Frontiers PDB-101: Diabetes Mellitus: Diabetes Mellitus:

Oxid Med Cell Longev 2017:9245702

This variability likely reflects differences in study populations, such as the presence or absence of T2DM, degree of obesity, sex distribution, and comorbid conditions, as well as differences in intervention characteristics, including the type, dose, and duration of GLP-1 RA therapy

Digestive tract immaturity and frequent complications appearing during the first weeks of life will make it difficult to implement an enteral nutrition enough to meet the metabolic needs of the preterm newborn (PTNB)

Biocompatible Polyurea Dendrimers with pH-Dependent Fluorescence

doi: 10.1126/scitranslmed.aao5563 172 BiasiSDSimoneAMBianchiniETartaroDLPecoriniSNasiMet al

A., Pihoker, C